Thoth CEO Featured in Leap Magazine for Discovery of Compound B – A Potent Nanomolar Immunomodulator

We’re proud to share that Dr. Khaled Barakat, CEO of Thoth Biosimulations, was featured in the Spring 2025 issue of Leap Magazine for his groundbreaking discovery of Compound B — a novel small molecule immunomodulator with nanomolar potency.

The article highlights Dr. Barakat’s multidisciplinary approach, combining biophysics, computational modeling, and drug design to unlock the immune system’s potential against cancer. Compound B holds promise as a dual-action agent: overcoming immune cell anergy and inducing apoptosis in cancer cells.

This recognition reinforces Thoth’s commitment to harnessing the power of science and innovation to deliver next-generation therapeutics with precision and purpose.

You can read the full feature in Leap Magazine, published by the Alberta Cancer Foundation.